Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012-Reference-Cited by-同舟云学术

Clinical Trial Evidence Supporting FDA Approval of Novel Therapeutic Agents, 2005-2012

Published:2014-01-22 Issue:4 Volume:311 Page:368
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Downing Nicholas S.¹,Aminawung Jenerius A.²,Shah Nilay D.³,Krumholz Harlan M.⁴,Ross Joseph S.⁵

Affiliation:

1. Yale University School of Medicine, New Haven, Connecticut

2. Section of General Internal Medicine, Department of Internal Medicine, Yale University School of Medicine

3. Division of Health Care Policy and Research, Mayo Clinic, Rochester, Minnesota

4. Division of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine4Robert Wood Johnson Clinical Scholars Program, Department of Internal Medicine, Yale University School of Medicine5Section of Health Policy and Admini

5. Section of General Internal Medicine, Department of Internal Medicine, Yale University School of Medicine4Robert Wood Johnson Clinical Scholars Program, Department of Internal Medicine, Yale University School of Medicine5Section of Health Policy and Admin

Publisher

American Medical Association (AMA)

Subject

General Medicine

Cited by 335 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug delivery strategies for local immunomodulation in transplantation: Bridging the translational gap;Advanced Drug Delivery Reviews;2024-10

2. Clinical trial evidence supporting FDA approval of novel orphan drugs between 2017 and 2023;Drug Discovery Today;2024-09

3. Biomarkers for gene therapy clinical trials of lysosomal storage disorders;Molecular Therapy;2024-09

4. Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies;JAMA Network Open;2024-08-27

5. Clinical Evidence Supporting FDA Approval of Gene and RNA Therapies for Rare Inherited Conditions;Pediatric Drugs;2024-08-05